Molbio Diagnostics IPO Review

Molbio Diagnostics Ltd. (MDL) is an innovative point-of-care (“POC”) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies to diagnose infectious and non-communicable diseases. It has developed ‘Truenat’ platform, which is a novel POC polymerase chain reaction (“PCR”) platform that can operate in resource limited settings since its battery operated, facilitating decentralized diagnosis within an hour. As of March 31, 2026, Truenat is patented in more than 100 countries for the diagnosis of multiple infectious and non-communicable diseases. 

As of March 31, 2026, it offers molecular testing for 30 diseases, including tuberculosis (“TB”), COVID, Hepatitis B and C, Human immunodeficiency virus (“HIV”), and Human Papillomavirus (“HPV”) with 43 assays. MDL operates in an oligopolistic market with high entry barriers, evidenced by the fact that its platform underwent 13 years of R&D to obtain Indian Council of Medical Research (“ICMR”) certification and ‘Truenat’ test chip for diagnosing TB is the only one by an Indian company and one of the only two rapid molecular tests in the world, which has been endorsed by the World Health Organization (“WHO”) for initial diagnosis of TB and rifampicin resistance detection using molecular diagnostic technology. (Source: 1Lattice Report). 

The company also provide devices, enabling radiology, digital pathology and breast health screening, through its Subsidiaries, Prognosys and OptraScan and collaboration partner - UE Lifesciences. Further, it is focused towards building a pipeline of additional products and platforms that are currently at various stages of development. The total addressable market for global POCT (based on the number of tests conducted) currently stands at USD 29.3 billion (equivalent to Rs. 2588.6 billion) (infectious and non-infectious diseases) and is projected to grow at CAGR of 17.9% between 2025 and 2030 to be a USD 67.1 billion (equivalent to Rs. 5928.2 billion) market by 2030. (Source: 1Lattice Report) Infectious diseases remain one of the most critical global health challenges, accounting for approximately 31.0% (19.4 million) of global deaths in 2023. Of the estimated 1.5 million deaths globally caused by infectious diseases like TB, hepatitis and HPV, an average of over 4,100 deaths occurred daily. (Source: 1Lattice Report) Limited access to affordable diagnostics solutions, inadequate infrastructure, including electricity and laboratory resources, and a lack of facilities pose significant obstacles to providing healthcare for patients with infectious and non-communicable diseases, particularly in underserved populations across the globe. (Source: 1Lattice Report).

Molecular diagnostics tests play a crucial role in detecting specific infectious and non-communicable diseases, conditions, and genetic variances, enabling healthcare providers to enhance patient outcomes and reduce healthcare costs by facilitating early and accurate disease diagnosis and improved disease monitoring. (Source: 1Lattice Report). Its ‘Truenat’ platform, equipped with fully automated, user-friendly features such as portability, simple workflow and rapid sample-to-result turnaround time, is designed to perform a wide array of tests swiftly and efficiently with high sensitivity and specificity compared to conventional diagnostic methods. (Source: 1Lattice Report) These features address the challenges faced by underserved populations worldwide, including limited access to diagnostic facilities, cost-effective diagnostic solutions, timely detection and treatment of diseases and electricity-dependent laboratory infrastructure. (Source: 1Lattice Report).

The company aims to establish a new standard of healthcare by ensuring accessibility to advanced testing technology for underserved populations globally through portable and cost effective testing solutions that deliver accurate results, ensuring essential medical care. Its ‘Truenat’ platform comprises two portable instruments - the Trueprep universal nucleic acid extraction device, which performs fully automated sample preparation; and the Truelab analyzer, which conducts real-time PCR and is available in three variants: UnoDx, Duo, and Quattro, which are capable of performing one, two, and four tests simultaneously, respectively. These tests are conducted using its disease-specific ‘Truenat’ test kits. These test kits are ready-to-use, room temperature stable, single-use consumables that are pre-loaded with necessary reagents required to conduct a real-time PCR test on the Truelab analyzers.

MDL offers its products globally to public health programs, diagnostic laboratories, and private and public hospitals. Till March 31, 2026, it has sold over 12,500 devices in over 90 countries. It derives a portion of revenues from the sale of its products to the Indian central and state governments, and international aid agencies for their public healthcare programs. Its revenue from such government and international aid agencies was 84.56%, 87.83% and 91.60% of its revenue from contracts with customers – sale of products - finished goods in Fiscals 2026, 2025 and 2024, respectively. Any unfavorable policy changes by these agencies or a decrease in funding for public healthcare programs may impact the sale of its products and adversely affect its business, financial condition, results of operations and cash flows. 

The company depends on a few suppliers for the supply of some of its raw materials and any disruption in the supply or increase in the prices of raw materials could adversely affect its business, financial condition, results of operations and cash flows. It derives revenues from the sale of ‘Truenat’ platform, which is designed to work exclusively with its range of ‘Truenat’ test kits that generate recurring revenues. A key feature of its platform is its versatility in diagnostic applications accommodating tests for various infectious and non-communicable diseases. MDL’s platform is designed to connect wirelessly to help healthcare providers manage clinical data and workflow online. This could assist with the transmission of ‘notifiable infections’ to public health authorities to facilitate the tracking of reportable diseases. This capability also enables it to remotely manage platform, such as providing remote software updates. According to the 1Lattice Report, its platform is cost-effective for healthcare providers on a long-term basis in terms of initial capital expenditure required for its installation as well as recurring costs per test.

It is focused on strengthening capabilities and expanding offerings through strategic acquisitions and collaborations with various organizations. This acquisition enabled it to provide end-to-end screening and confirmatory tests for TB at the community level. Further, Prognosys has also expanded its presence in the animal healthcare imaging market through veterinary diagnostic imaging products and veterinary software applications. Further, in October 2024, Company entered into a stock purchase agreement to invest and hold 60.00% of the paid-up equity share capital of OptraScan INC. Pursuant to which, in November 2024, it received the share certificate in respect of the first tranche investment, acquiring 19.68%, equity stake in OptraScan INC., a USA based company which provides digital pathology solutions, offering a range of digital pathology scanners, AI-powered analysis tools, and telepathology services, enabling remote consultations and collaboration.

MDL has six manufacturing facilities in India, of which two are in Goa, one in Bengaluru, Karnataka and one in Visakhapatnam, Andhra Pradesh which are operated by it and dedicated to manufacturing of devices and test kits, one in Bengaluru, Karnataka is operated by its Subsidiary, Prognosys Medical Systems Private Limited and is dedicated to manufacturing of radiology products such as ultraportable X-ray systems, mobile digital X-ray systems, floor-mounted and ceiling-suspended X-ray systems and C-arm systems, and one in Pune, Maharashtra is operated by its Subsidiary, OptraScan India Private Limited and is dedicated to manufacturing of digital pathology scanners. As of March 31, 2026, its installed capacity was 5,400 devices per annum and 39,000,000 ‘Truenat’ test kits per annum. In the Fiscals 2026, 2025 and 2024, its capacity utilization was 42.30%, 58.89% and 19.83% for devices and 58.25%, 43.44% and 27.45% for test kits, respectively, indicating that its manufacturing infrastructure is prepared for future growth since the company made early investments in it. The company also collaborate with electronic manufacturing services (“EMS”) vendors to assemble Truenat devices as and when required to meet demand. It has leveraged automation to enhance precision and efficiency in processes, ensuring that its products are of high quality and reliable. As of March 31, 2026, it had 1225 employees on its payroll and additional 1615 contract labourers in various departments.